CROI 2015: Advances in HIV testing and prevention strategies

Topics in Antiviral Medicine

Volumn 23, Issue 1, 2015, Pages 8-27

  Buchbinder, Susan P ^a   Liu, Albert Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CROI 2015; Epidemiology; HIV; Incidence; Injection drug use; Men who have sex with men; MSM; Phylogenetics; Preexposure prophylaxis; PrEP; Prevention; Serodiscordant couples; Testing; Transmission; Treatment as prevention

Indexed keywords

CABOTEGRAVIR; CD38 ANTIGEN; CENTRAL STIMULANT AGENT; CHEMOKINE RECEPTOR CCR5; DAPIVIRINE; EFAVIRENZ; EMTRICITABINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LOPINAVIR; MARAVIROC; MEDROXYPROGESTERONE ACETATE; NEVIRAPINE; NORETHISTERONE ENANTATE; OPIATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALTEGRAVIR; RILPIVIRINE; SYNDECAN; TENOFOVIR DISOPROXIL; TUMOR NECROSIS FACTOR ALPHA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; GENE MUTATION; GENITAL ULCER; GONORRHEA; HEALTH CARE COST; HEPATITIS C VIRUS; HIV SEROSORTING; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); NEPHROTOXICITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHYLOGENY; POLYMERASE CHAIN REACTION; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SOCIOECONOMICS; SYPHILIS; TRANSACTIONAL SEX; VIRUS TRANSMISSION; FEMALE; HIV INFECTIONS; MALE; MEDICATION COMPLIANCE; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; SEXUALITY; UNITED STATES;

ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PRE-EXPOSURE PROPHYLAXIS; SEXUAL PARTNERS; UNITED STATES;

EID: 84928956011     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12(1):e1001778.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27): 2587-2599.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-434.
5. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
6. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015; 372(6):509-518.
7. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.
8. Cottrell ML, Yang KH, Prince HMA, et al. Predicting effective truvada® PrEP dosing strategies with a novel PKPD model incorporating tissue active metabolites and endogenous nucleotides (EN). AIDS Res Hum Retroviruses. 2014;30(S1):A60.
9. Abbas UL, Anderson RM, Mel lors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One. 2007;2(9):e875.
10. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral preexposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021-1028.
11. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U.S.A. 2010;107(27):12381-12386.
12. van de Vijver DA, Nichols BE, Abbas UL, et al. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS. 2013;27(18):2943-2951.
13. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014;S1473-S3099 [Epub ahead of print].
14. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
15. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP Demonstration Project. J Acquir Immune Defic Syndr. 2015;68(4):439-448.
16. Liu AY. Implementation of PrEP in STD and community health clinics: high uptake and drug concentrations among MSM in the Demo Project [Abstract 377]. 9th International Conference on HIV Treatment and Prevention Adherence. June 8-10, 2014; Miami, Florida.
17. Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712-1721.
18. Kahle EM, Hughes JP, Lingappa JR, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62(3):339-347.
19. Karim QA, Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection women. Science. 2010;329(5996):1168-1174.
20. World Heal th Organizat ion. Post-exposure prophylaxis to prevent HIV infection: Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. http://whqlibdoc.who.int/publications/2007/9789241596374_eng.pdf?ua=1. Accessed on April 6, 2015.